Skip to main content
Top

18-12-2024 | Parkinson Disease | Letter to the Editor

Subcutaneous administration of foslevodopa/foscarbidopa (PRODUODOPA®) in arm and thigh due to giant epigastric hernia: a case report

Authors: Srđana Telarović, Lucija Čondić Jurjević

Published in: Neurological Sciences

Login to get access

Abstract

Background

PRODUODOPA® is a combination of foscarbidopa and foslevodopa indicated for the treatment of motor fluctuations in patients with advanced Parkinson’s disease when available combinations of peroral drugs have not given satisfactory results. The solution is administered via subcutaneous infusion, most frequently in the abdomen, using an infusion pump. The study results showed a significant effect on the reductions in off time and higher control of motor symptoms without troublesome dyskinesia.

Case description

A 61-year-old man on long-term oral therapy for Parkinson’s disease presented with frequent wearing-off phenomenon, daily freezing episodes and occasional episodes of severe nocturnal akinesia. Due to giant epigastric hernia PRODUODOPA was administered subcutaneously in upper arm and thigh. The use of the pump resulted in an excellent therapeutic effect with a reduction in motor fluctuations and an improvement in the patient’s quality of life. From the available medical literature, the use of the drug in the limb area has not been described so far.

Conclusion

PRODUODOPA can be administered subcutaneously in the area of ​​the upper and lower extremities with just as good results as after subcutaneous infusion in abdomen.
Literature
1.
go back to reference Jankovic J, Tan EK (2020) Parkinson’s disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry 91:795–808CrossRefPubMed Jankovic J, Tan EK (2020) Parkinson’s disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry 91:795–808CrossRefPubMed
4.
go back to reference Alexoudi A, Alexoudi I, Gatzonis S (2018) Parkinson’s disease pathogenesis, evolution and alternative pathways: a review. Rev Neurol (Paris) 174(10):699–704CrossRefPubMed Alexoudi A, Alexoudi I, Gatzonis S (2018) Parkinson’s disease pathogenesis, evolution and alternative pathways: a review. Rev Neurol (Paris) 174(10):699–704CrossRefPubMed
7.
go back to reference Xie T, Vigil J, MacCracken E, Gasparaitis A, Young J, Kang W, Bernard J, Warnke P, Kang UJ (2015) Low-frequency stimulation of STN-DBS reduces aspiration and freezing of gait in patients with PD. Neurology 84(4):415CrossRefPubMedPubMedCentral Xie T, Vigil J, MacCracken E, Gasparaitis A, Young J, Kang W, Bernard J, Warnke P, Kang UJ (2015) Low-frequency stimulation of STN-DBS reduces aspiration and freezing of gait in patients with PD. Neurology 84(4):415CrossRefPubMedPubMedCentral
8.
go back to reference Aldred J, Freire-Alvarez E, Amelin AV, Antonini A, Bergmans B, Bergquist F, Bouchard M, Budur K, Carroll C, Chaudhuri KR, Criswell SR, Danielsen EH, Gandor F, Jia J, Kimber TE, Mochizuki H, Robieson WZ, Spiegel AM, Standaert DG, Talapala S, Facheris MF, Fung VSC (2023) Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy results from a 12-Month, Single-Arm, Open-Label, phase 3 study. Neurol Ther 12(6):1937–1958. https://doi.org/10.1007/s40120-023-00533-1CrossRefPubMedPubMedCentral Aldred J, Freire-Alvarez E, Amelin AV, Antonini A, Bergmans B, Bergquist F, Bouchard M, Budur K, Carroll C, Chaudhuri KR, Criswell SR, Danielsen EH, Gandor F, Jia J, Kimber TE, Mochizuki H, Robieson WZ, Spiegel AM, Standaert DG, Talapala S, Facheris MF, Fung VSC (2023) Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy results from a 12-Month, Single-Arm, Open-Label, phase 3 study. Neurol Ther 12(6):1937–1958. https://​doi.​org/​10.​1007/​s40120-023-00533-1CrossRefPubMedPubMedCentral
9.
go back to reference Soileau MJ, Aldred J, Budur K, Fisseha N, Fung VS, Jeong A, Kimber TE, Klos K, Litvan I, O’Neill D, Robieson WZ, Spindler MA, Standaert DG, Talapala S, Vaou EO, Zheng H, Facheris MF, Hauser RA (2022) Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson’s disease: a randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol 21(12):1099–1109. https://doi.org/10.1016/S1474-4422(22)00400-8CrossRefPubMed Soileau MJ, Aldred J, Budur K, Fisseha N, Fung VS, Jeong A, Kimber TE, Klos K, Litvan I, O’Neill D, Robieson WZ, Spindler MA, Standaert DG, Talapala S, Vaou EO, Zheng H, Facheris MF, Hauser RA (2022) Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson’s disease: a randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol 21(12):1099–1109. https://​doi.​org/​10.​1016/​S1474-4422(22)00400-8CrossRefPubMed
11.
go back to reference Martinez-Martin P, Reddy P, Katzenschlager R, Antonini A, Todorova A, Odin P et al (2015) EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson’s disease. Mov Disord 30(4):510–516CrossRefPubMed Martinez-Martin P, Reddy P, Katzenschlager R, Antonini A, Todorova A, Odin P et al (2015) EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson’s disease. Mov Disord 30(4):510–516CrossRefPubMed
12.
go back to reference Juhasz A, Aschermann Z, Acs P, Janszky J, Kovacs M, Makkos A et al (2017) Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson’s disease: an open-label study. Parkinsonism Relat Disord 37:79–86CrossRefPubMed Juhasz A, Aschermann Z, Acs P, Janszky J, Kovacs M, Makkos A et al (2017) Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson’s disease: an open-label study. Parkinsonism Relat Disord 37:79–86CrossRefPubMed
13.
go back to reference Lopiano L, Modugno N, Marano P, Sensi M, Meco G, Solla P et al (2019) Motor and non-motor outcomes in patients with advanced Parkinson’s disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study. J Neurol 266(9):2164–2176CrossRefPubMedPubMedCentral Lopiano L, Modugno N, Marano P, Sensi M, Meco G, Solla P et al (2019) Motor and non-motor outcomes in patients with advanced Parkinson’s disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study. J Neurol 266(9):2164–2176CrossRefPubMedPubMedCentral
14.
go back to reference Virhammar J, Nyholm D (2017) Levodopa-carbidopa enteral suspension in advanced Parkinson’s disease: clinical evidence and experience. Ther Adv Neurol Disord 10(3):171–187CrossRefPubMed Virhammar J, Nyholm D (2017) Levodopa-carbidopa enteral suspension in advanced Parkinson’s disease: clinical evidence and experience. Ther Adv Neurol Disord 10(3):171–187CrossRefPubMed
15.
go back to reference PRODUODOPA® (2023) (foslevodopa/foscarbidopa solution for infusion) Summary of Product Characteristics PRODUODOPA® (2023) (foslevodopa/foscarbidopa solution for infusion) Summary of Product Characteristics
Metadata
Title
Subcutaneous administration of foslevodopa/foscarbidopa (PRODUODOPA®) in arm and thigh due to giant epigastric hernia: a case report
Authors
Srđana Telarović
Lucija Čondić Jurjević
Publication date
18-12-2024
Publisher
Springer International Publishing
Published in
Neurological Sciences
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-024-07928-4

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now
Video

Advances in Alzheimer's

Alzheimer's research and care is changing rapidly. Keep up with the latest developments from key international conferences, together with expert insights on how to integrate these advances into practice.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Healthcare IME
Learn more